Rolipram

• Background:

  Rolipram has been observed to selectively inhibit cAMP-phosphodiesterase (PDE4) by recruiting PDE4 into cytosolic aggregates that are not membrane-encapsulated. A down-stream effect of this observation is the inhibition of autophagy. Under normal conditions, autophagosomes are coated with the autophagic marker light chain 3 (LC3). LC3 binds directly to p62 protein, which shuttles protein to aggresomes, eventually leading to an autophagic event. In the absence of LC3, protein aggregates will not undergo autophagy, and will remain as cytosolic aggregates, as seen with the inhibition of PDE4 by Rolipram. It promotes axonal regeneration (4).

• Description:

  Autophagy inhibitor

• Product Name Alternative:

  4- (3- (Cyclopentyloxy) -4-methoxyphenyl) pyrrolidin-2-one

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cancer | Autophagy | Neuroscience | Neurodegeneration | Neurogenesis

• Purity:

  >98% (TLC) ; NMR (Conforms)

• Weight:

  0.01

• Format:

  White to off-white solid.

• Solubility:

  Soluble to 75 mM in DMSO and to 75 mM in ethanol.

• Molecular Formula:

  C16H21NO3

• Molecular Weight:

  275.35

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Kato H., et al. (1995) Eur J Pharmacol. 272(1): 107-10. 2. Christian F., et al. (2010) Cell Signal. 22(10): 1576-96. 3. Houslay M.D., & Christian F. (2010) Autophagy. 6(8): 1198-200. 4. E Nikulina et al PNAS; 2004; 101, 8786

• CAS Number:

  61413-54-5